This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossier, P. Articles by Wade, D. T Search for Related Content PubMed PubMed Citation Articles by Rossier, P. Articles by Wade, D. T Social Bookmarking                   What's this?

The Guy's Neurological Disability Scale in patients with multiple sclerosis: a clinical evaluation of its reliability and validity

Derick T Wade

Rivermead Rehabilitation Centre, Oxford, UK

Objective: To establish reliability and validity of the Guy's Neurological Disability Scale (GNDS) for the assessment of patients with multiple sclerosis (MS) and to investigate whether it can be used by postal questionnaire.

Design: An observational study assessing one group of 22 patients using the GNDS face-to-face, repeating the assessment two or three weeks later with other tests; and assessing a second group of 21 patients first using a postal version of the GNDS and then seeing them face-to-face.

Setting: Patients in the community attending a day centre or a voluntary support group.

Subjects: Patients with multiple sclerosis.

Measures: The GNDS was the primary measure, and was compared with the Barthel Index, the Expanded Disability Status Scale (EDSS), the Short Orientation Concentration and Memory Test, the Nine-hole Peg Test, the Rivermead Mobility Index, the Hospital Anxiety and Depression Scale, the Fatigue Severity Scale, visual acuity assessment, swallowing 50 ml of water, and a clinical assessment of dysarthria.

Results: The test–retest reliability of the GNDS total score (r = 0.972) and each of its components (r varied from 0.685 to 0.987) was good. When compared with the EDSS or the Barthel, the GNDS had good validity (respectively r = 0.636 and r = –0.757). The validity was also measured for the different areas of the GNDS by comparison with corresponding indices or test. The results varied from good to excellent (r from –0.557 to 0.910). The results were only a little less reliable when a postal questionnaire was used.

Conclusion: The GNDS is a valid and reliable tool for the assessment of MS patients. The test–retest correlation varies from good to excellent. It can be used as postal questionnaire even if, as expected, the intervieweradministered method shows slightly better results.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M A Newman, H Dawes, M van den Berg, D T Wade, J Burridge, and H Izadi Can aerobic treadmill training reduce the effort of walking and fatigue in people with multiple sclerosis: a pilot study Multiple Sclerosis, January 1, 2007; 13(1): 113 - 119. [Abstract] [PDF]

				D T Wade, P M Makela, H House, C Bateman, and P Robson Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis Multiple Sclerosis, September 1, 2006; 12(5): 639 - 645. [Abstract] [PDF]

				M van den Berg, H Dawes, D T Wade, M Newman, J Burridge, H Izadi, and C M Sackley Treadmill training for individuals with multiple sclerosis: a pilot randomised trial J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 531 - 533. [Abstract] [Full Text] [PDF]

				T. Wesselius, D. J. Heersema, J. P. Mostert, M. Heerings, F. Admiraal-Behloul, A. Talebian, M. A. van Buchem, and J. De Keyser A randomized crossover study of bee sting therapy for multiple sclerosis Neurology, December 13, 2005; 65(11): 1764 - 1768. [Abstract] [Full Text] [PDF]

				O.R. Pearson, M.E. Busse, R.W.M. van Deursen, and C.M. Wiles Quantification of walking mobility in neurological disorders QJM, August 1, 2004; 97(8): 463 - 475. [Full Text] [PDF]

				D. T Wade, P. Makela, P. Robson, H. House, and C. Bateman Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients Multiple Sclerosis, August 1, 2004; 10(4): 434 - 441. [Abstract] [PDF]

				A. J Thompson Developing clinical outcome measures in multiple sclerosis: an evolving process Multiple Sclerosis, October 1, 2002; 8(5): 357 - 358. [PDF]

				D T Wade, C A Young, K R Chaudhuri, and D L W Davidson A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, September 1, 2002; 73(3): 246 - 249. [Abstract] [Full Text] [PDF]